Literature DB >> 25056847

Expressional changes of genes and miRNA in common megakaryocyte-erythroid progenitors from lower-risk myelodysplastic syndrome.

Kazuhiro Maki1, Ko Sasaki, Yasunobu Nagata, Fusako Nagasawa, Yuka Nakamura, Seishi Ogawa, Kinuko Mitani.   

Abstract

Myelodysplastic syndrome (MDS) is a stem cell tumor characterized by dysplastic features and ineffective hematopoiesis in the early phase and leukemic progression in the late phase. Speculating that differences in the expression of genes and microRNA (miRNA) in control and MDS-derived erythroid progenitors may cause ineffective erythropoiesis, we sorted common megakaryocyte-erythroid progenitors (MEPs) in bone marrow cells from three lower-risk MDS patients, and compared expression levels of genes and miRNA with those from controls. In apoptosis-related pathways, the expression of some pro-apoptotic genes, such as cell death-inducing DFFA-like effector A, caspase 5, and Fas ligand, was elevated in MDS-derived MEPs, while those of anti-apoptotic CD40 and tumor necrosis factor were lower. In hematopoiesis-regulating pathways, RUNX1 and ETV6 genes showed reduced expression. Expression profiling revealed that three and 35 miRNAs were significantly up- and down-regulated in MDS-derived MEPs. MIR9 exhibited robust expression in MEPs and CD71+GlyA+ erythroid cells derived from one of the three patients. Interestingly, overexpression of MIR9 inhibited the accumulation of hemoglobin in UT-7/GM cells. Some of these alterations in gene and miRNA expression may contribute to the pathogenesis of ineffective hematopoiesis in lower-risk MDS and provide molecular markers for sub-classification and making a prognosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25056847     DOI: 10.1007/s12185-014-1639-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  40 in total

1.  Aberrant microRNA expression pattern in myelodysplastic bone marrow cells.

Authors:  Kais Hussein; Katharina Theophile; Guntram Büsche; Brigitte Schlegelberger; Gudrun Göhring; Hans Kreipe; Oliver Bock
Journal:  Leuk Res       Date:  2010-06-03       Impact factor: 3.156

Review 2.  Epigenetic aspects of MDS and its molecular targeted therapy.

Authors:  Jumpei Yamazaki; Jean-Pierre J Issa
Journal:  Int J Hematol       Date:  2012-10-10       Impact factor: 2.490

3.  Diagnostic microRNAs in myelodysplastic syndrome.

Authors:  Begum Erdogan; Crystal Facey; Julianne Qualtieri; Jason Tedesco; Elizabeth Rinker; R Benjamin Isett; John Tobias; Donald A Baldwin; James E Thompson; Martin Carroll; Annette S Kim
Journal:  Exp Hematol       Date:  2011-06-15       Impact factor: 3.084

Review 4.  AML1/Runx1 as a versatile regulator of hematopoiesis: regulation of its function and a role in adult hematopoiesis.

Authors:  Mineo Kurokawa
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

Review 5.  Border between aplastic anemia and myelodysplastic syndrome.

Authors:  Hirohito Yamazaki; Shinji Nakao
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

6.  Hematopoiesis-related microRNA expression in myelodysplastic syndromes.

Authors:  Aina Pons; Benet Nomdedeu; Alfons Navarro; Anna Gaya; Bernat Gel; Tania Diaz; Sandra Valera; María Rozman; Mohamed Belkaid; Emili Montserrat; Mariano Monzo
Journal:  Leuk Lymphoma       Date:  2009-11

7.  Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

Authors:  Masashi Sanada; Takahiro Suzuki; Lee-Yung Shih; Makoto Otsu; Motohiro Kato; Satoshi Yamazaki; Azusa Tamura; Hiroaki Honda; Mamiko Sakata-Yanagimoto; Keiki Kumano; Hideaki Oda; Tetsuya Yamagata; Junko Takita; Noriko Gotoh; Kumi Nakazaki; Norihiko Kawamata; Masafumi Onodera; Masaharu Nobuyoshi; Yasuhide Hayashi; Hiroshi Harada; Mineo Kurokawa; Shigeru Chiba; Hiraku Mori; Keiya Ozawa; Mitsuhiro Omine; Hisamaru Hirai; Hiromitsu Nakauchi; H Phillip Koeffler; Seishi Ogawa
Journal:  Nature       Date:  2009-07-20       Impact factor: 49.962

8.  Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; José Adélaïde; Julien Bonansea; Nathalie Cervera; Nadine Carbuccia; Arnaud Lagarde; Thomas Prebet; Meyer Nezri; Danielle Sainty; Sylviane Olschwang; Luc Xerri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2009-04-15       Impact factor: 6.998

Review 9.  Differential regulation of cell survival by CD40.

Authors:  C Dallman; P W M Johnson; G Packham
Journal:  Apoptosis       Date:  2003-01       Impact factor: 4.677

10.  Acquired mutations in TET2 are common in myelodysplastic syndromes.

Authors:  Saskia M C Langemeijer; Roland P Kuiper; Marieke Berends; Ruth Knops; Mariam G Aslanyan; Marion Massop; Ellen Stevens-Linders; Patricia van Hoogen; Ad Geurts van Kessel; Reinier A P Raymakers; Eveline J Kamping; Gregor E Verhoef; Estelle Verburgh; Anne Hagemeijer; Peter Vandenberghe; Theo de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

View more
  2 in total

1.  Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre.

Authors:  Huijun Huang; Changlu Xu; Jie Gao; Bing Li; Tiejun Qin; Zefeng Xu; Sirui Ren; Yudi Zhang; Meng Jiao; Shiqiang Qu; Lijuan Pan; Naibo Hu; Jinqin Liu; Wenyu Cai; Yingnan Zhang; Dan Wu; Peihong Zhang; Robert Peter Gale; Gang Huang; Jiaxi Zhou; Lihong Shi; Zhijian Xiao
Journal:  Blood Cancer J       Date:  2020-08-14       Impact factor: 11.037

Review 2.  Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins.

Authors:  Marcus Bauer; Christoforos Vaxevanis; Nadine Heimer; Haifa Kathrin Al-Ali; Nadja Jaekel; Michael Bachmann; Claudia Wickenhauser; Barbara Seliger
Journal:  Int J Mol Sci       Date:  2020-09-27       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.